New Delhi: As part of the vaccination trial for children in the age group of 2-6 years, the second dose of Covaxin is likely to be administered next week.
A report in India Today quoted All India Institute of Medical Sciences (AIIMS) Delhi officials as saying that the second dose of Covaxin has already been administered to those who are part of the trial in 6-12 age group.
Kids’ trials for Covaxin, the indigenous vaccine developed by Hyderabad-based Bharat Biotech, is being pushed keeping in mind the third wave of the COVID-19 pandemic which experts have said is inevitable in India.
Once all 175 participants in the 2-6 age group trial have received the second dose, an interim report is expected by the end of August. Based on the trial report, it will be decided if the vaccine is safe for children.
AIIMS director Dr Randeep Guleria said earlier that Covaxin is likely to be approved for children in September.
Covaxin apart, Zydus Cadila’s three-dose shot ZyCov-D is the other vaccine which experts believe could be approved for children in a few months’ time.
Comments are closed.